Selpercatinib

The FDA has granted accelerated approval to selpercatinib (Retevmo; Eli Lilly and Company) for pediatric patients aged 2 years and older with RET-altered metastatic thyroid cancer or solid tumors, the federal agency announced in a press release. Selpercatinib is a highly selective, potent RET inhibitor. It works by blocking a type of enzyme (kinase) and helps prevent the cancer cells from growing.